- Home
- MDIA vs ELOX Comparison
MDIA vs ELOX Comparison
Compare MDIA & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDIA | ELOX |
|---|---|---|
| Founded | 2019 | N/A |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Broadcasting | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.0M | 43.8M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | MDIA | ELOX |
|---|---|---|
| Price | $0.77 | $12.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 116.5K | 12.5K |
| Earning Date | 05-19-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $133,336,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 39.52 | N/A |
| 52 Week Low | $0.54 | $12.90 |
| 52 Week High | $1.64 | $14.28 |
Technical Indicators
Market Signals| Indicator | MDIA | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 45.72 | N/A |
| Support Level | $0.59 | N/A |
| Resistance Level | $0.99 | N/A |
| Average True Range (ATR) | 0.15 | 0.00 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 10.99 | 0.00 |
Price Performance
Historical ComparisonAbout MDIA Mediaco Holding Inc.
MediaCo Holding Inc is a radio broadcasting media company operating in radio and digital advertising, premium programming, and events. It has two radio stations, WQHT-FM and WBLS-FM, which serve the New York City metropolitan area. The company generates revenue from radio and outdoor advertising sales, events including sponsorships and ticket sales, licensing, and syndication. The company has two business segments: the Audio segment and the Video segment. The company generates the majority of its revenue from the Audio segment.
About ELOX Eloxx Pharmaceuticals Inc. Common Stock
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.